Purpose: To compare iStent inject® W+phacoemulsification with XEN45 implant+phacoemulsification over 12 months in mild to moderate glaucoma patients needing cataract surgery at the Hospital General Universitario Dr. Balmis, Alicante, Spain.
Methods: Retrospective clinical cohort study. Consecutive patients who underwent phacoemulsification either combined with XEN45 implantation or iStent inject® W from 2020 to 2022 were included. The main outcome measure was surgical success at 12 months postoperatively. Intraocular pressure (IOP), number of antiglaucoma medications, intraoperative and postoperative complications, number of revision surgeries, use of the operating room and required visits were also evaluated.
Results: A total of 167 eyes were included in the study, with 101 eyes of 61 patients undergoing iStent+PHACO and 66 eyes of 46 patients undergoing XEN45+PHACO. The proportion of patients achieving a complete success (IOP≥5 and ≤ 18mmHg without medication) at the conclusion of the 12-month follow-up was 47.9% (35/73) in the iStent+PHACO and 48.2% (27/56) in the XEN45+PHACO surgery group, P=1.000. The mean (95% CI) IOP reduction at the conclusion of the study follow-up was -2.4 (-3.5 to -1.3mmHg, P<0.001, iStent+PHACO) and -3.10 (-4.8 to -1.4mmHg, P<0.001, XEN45+PHACO). The mean number of antiglaucoma medications was significantly reduced in both study groups. Rates of intraoperative complications (5 vs. 15.2%), postoperative complications (1 vs. 46.2%), reoperations (0 vs. 24.6%), mean number of operating room visits (1 vs. 1.41), and mean number of required postoperative visits (4.50 vs. 11.13) were all statistically significantly higher in the XEN45+PHACO group (< 0.001).
Conclusions: Both procedures achieved similar surgical success rates, with comparable reductions in IOP and the number of antiglaucoma medications. After one year, a modest IOP reduction of 10.83% was observed in the iStent group and 13.65% in the Xen group. However, the iStent inject® W demonstrated a better intraoperative and postoperative safety profile.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jfo.2025.104469 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison between Phacoemulsification-iStent Inject W and Phacoemulsification-Micropulse Transscleral Laser Therapy in Asian Eyes with Mild-Moderate Open Angle Glaucoma.
J Glaucoma
March 2025
Department of Ophthalmology, National University Hospital, National University Health System.
Prcis: In this retrospective cohort study, the 1-year cumulative probability of failure was comparable, achieving 52.20% in the phacoemulsification-iStent inject W (phaco/iStent) group and 47.80% in the phacoemulsification-micropulse transscleral laser therapy (phaco/MPTLT) group (P=0.
View Article and Find Full Text PDFReal-world comparison of efficacy and safety of XEN45 implant with phacoemulsification versus iStent inject® W with phacoemulsification.
J Fr Ophtalmol
March 2025
Department of Ophthalmology, Hospital General Universitario Dr. Balmis, Alicante, Spain; Clínica Oftalvist, Alicante, Spain; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
Purpose: To compare iStent inject® W+phacoemulsification with XEN45 implant+phacoemulsification over 12 months in mild to moderate glaucoma patients needing cataract surgery at the Hospital General Universitario Dr. Balmis, Alicante, Spain.
Methods: Retrospective clinical cohort study.
Precise: In this article, we describe the development of validated software that automates cost-effectiveness analyses of minimally invasive glaucoma surgeries based on modifications to robust mathematical models of glaucoma progression and management discussed in previous literature.
Purpose: To develop a validated application to streamline use of cost-effectiveness (CE) in clinical management and investigations of minimally invasive glaucoma surgeries (MIGS) in the United States.
Design: Automated cost-utility analysis adapted from Markov models described in prior literature.
Comparison of the Intraocular Pressure-Lowering Effect of Minimally Invasive Glaucoma Surgery (MIGS) iStent Inject W and Hydrus-The 12-Month Real-Life Data.
Diagnostics (Basel)
February 2025
Department of Ophthalmology, University of Muenster Medical Center, Domagkstraße 15, 48149 Muenster, Germany.
To compare the efficacy and safety of Hydrus Microstent and iStent inject W implants, in combination with phacoemulsification, for lowering intraocular pressure (IOP) in patients with glaucoma in a real-world clinical setting. This retrospective, single-center study analyzed medical records of glaucoma patients who underwent either Hydrus Microstent or iStent inject W implantation combined with cataract surgery at the University Hospital Muenster, Germany. Key outcome measures included absolute and relative IOP reduction, reduction in topical antiglaucoma medication use, overall success rate, and complications.
View Article and Find Full Text PDFOutcomes and Complications of Minimally Invasive Glaucoma Surgeries (MIGS) in Primary Angle Closure and Primary Angle Closure Glaucoma: A Systematic Review and Meta-Analysis.
Clin Ophthalmol
February 2025
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
Topic: To analyse the safety and efficacy of minimally invasive glaucoma surgeries (MIGS) in lowering IOP and medication burden in primary angle closure (PAC) or primary angle closure glaucoma (PACG).
Clinical Relevance: MIGS is off-label in angle closure, as implantation of the device is difficult when there is iridotrabecular contact. However, access to the trabecular meshwork may be established with cataract removal or goniosynechiolysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!